Showing 7171-7180 of 7494 results for "".
- Valeant Pharmaceuticals Announces Appointment of Dr. Ari Kellen to Executive Management Teamhttps://practicaldermatology.com/news/20131125-valeant_pharmaceuticals_announces_appointment_of_dr_ari_kellen_to_executive_management_team/2459405/Valeant Pharmaceuticals International, Inc. announced that Dr. Ari Kellen has been named to Valeant's Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1,
- Lithera Announces Appointment of Dr. Lincoln Krochmal as Chief Medical Officerhttps://practicaldermatology.com/news/20131121-lithera_announces_appointment_of_dr_lincoln_krochmal_as_chief_medical_officer/2459407/Lincoln Krochmal, MD was recently appointed as Chief Medical Officer of Lithera, Inc. According to the company, this appointment reflects the company's continued growth as it prepares to enter la
- Consumer Survey Reveals Widespread Problem of Excessive Sweating and Desire for New Topical Botulinum Toxin Treatmenthttps://practicaldermatology.com/news/20131118-consumer_survey_reveals_widespread_problem_of_excessive_sweating_and_desire_for_new_topical_botulinum_toxin_treatment/2459412/Anterios, Inc announced survey results about current consumer sentiment around exces
- Antares Pharma Enters into Promotion and Marketing Agreement with LEO Pharma for Otrexuphttps://practicaldermatology.com/news/20131118-antares_pharma_enters_into_promotion_and_marketing_agreement_with_leo_pharma_for_otrexup/2459413/Antares Pharma, Inc. announced an exclusive agreement with LEO Pharma for the promotion and marketing of Otrexup (methotrexate) to dermatologists for symptomatic c
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde
- Signum Dermalogix Receives Grant for the Development of Atopic Dermatitis Therapeuticshttps://practicaldermatology.com/news/20131114-signum_dermalogix_receives_grant_for_the_development_of_atopic_dermatitis_therapeutics/2459415/The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Signum Dermalogix, Inc. (Dermalogix) a Small Business Innovat
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for th
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Restoration Robotics Announces the Launch Of ARTAS Hair Studio™https://practicaldermatology.com/news/20131025-restoration_robotics_announces_the_launch_of_artas_hair_studio/2459428/At this year's International Society of Hair Restoration Surgery (ISHRS) conference in San Francisco (October 23-27), Restoration Robotics will introduce the ARTAS Hair Studio™, a new product that expands the clinical indication and capability o
- Rigel Provides Pipeline Updatehttps://practicaldermatology.com/news/20131024-rigel_provides_pipeline_update/2459429/Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.